Bourne Lent Asset Management Inc. Invests $70,000 in RA Medical Systems Inc (NYSE:RMED)

Bourne Lent Asset Management Inc. bought a new position in RA Medical Systems Inc (NYSE:RMED) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 50,004 shares of the company’s stock, valued at approximately $70,000. Bourne Lent Asset Management Inc. owned 0.39% of RA Medical Systems as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of RMED. Dowling & Yahnke LLC purchased a new stake in shares of RA Medical Systems during the second quarter worth $110,000. BlackRock Inc. boosted its holdings in RA Medical Systems by 94.2% during the second quarter. BlackRock Inc. now owns 22,438 shares of the company’s stock valued at $81,000 after purchasing an additional 10,883 shares in the last quarter. Weil Company Inc. acquired a new stake in RA Medical Systems during the second quarter valued at approximately $63,000. Finally, Envestnet Asset Management Inc. acquired a new stake in RA Medical Systems during the second quarter valued at approximately $45,000. 21.86% of the stock is owned by institutional investors and hedge funds.

RMED stock opened at $1.62 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 11.89 and a quick ratio of 11.45. The company has a 50 day moving average price of $1.43 and a 200 day moving average price of $2.83. RA Medical Systems Inc has a fifty-two week low of $1.06 and a fifty-two week high of $11.75. The stock has a market capitalization of $20.00 million and a PE ratio of -0.49.

RMED has been the topic of a number of recent research reports. Piper Jaffray Companies downgraded RA Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $9.00 to $1.50 in a report on Tuesday, August 13th. Zacks Investment Research raised RA Medical Systems from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, Cantor Fitzgerald downgraded RA Medical Systems from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $10.00 to $2.00 in a report on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.38.

About RA Medical Systems

Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.

Recommended Story: Cash Asset Ratio

Institutional Ownership by Quarter for RA Medical Systems (NYSE:RMED)

Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.